Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Gladius Therapeutics logo — Developing groundbreaking therapies to disrupt mitochondrial...

Gladius Therapeutics

Developing groundbreaking therapies to disrupt mitochondrial function in cancer cells.

Biopharma, Biotechnology +1

General Information

Company Name Gladius Therapeutics
Industries Biopharma, Biotechnology, Life Sciences
Social

Get notified when Gladius Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Gladius Therapeutics

Gladius Therapeutics is a clinical-stage biopharmaceutical company focusing on developing groundbreaking therapies to disrupt mitochondrial function in cancer cells. The company's main focus lies in the biopharma and biotechnology industries. Despite the absence of specific details regarding the company's founding date, headquarters, and last investment round, Gladius Therapeutics is undoubtedly carving its path in the industry. The pioneering work of Gladius Therapeutics in disrupting cancer cell function through mitochondrial intervention is highly promising. The company's commitment to developing therapies that target such a crucial aspect of cancer cells demonstrates its potential to make a significant impact in the biopharmaceutical sector. With the absence of last investment details, it presents an opportunity for potential investors to dive into this innovative space and capitalize on the growing potential of Gladius Therapeutics. Overall, Gladius Therapeutics' strategic focus and potential for disruptive innovation position it as a promising candidate for investment consideration in the biopharmaceutical landscape.

Taxonomy: biopharmaceutical, clinical-stage, cancer therapy, mitochondrial function, cancer cells, oncology research, therapeutics development, innovative treatments

No funding data available for Gladius Therapeutics yet.

Get notified when Gladius Therapeutics raises funding

Gladius Therapeutics Alternatives & Competitors

Gladius Therapeutics vs
Galera Therapeutics, Inc.
Galera Therapeutics, Inc. United States

Transforming the science and treatment of cancer

IPO
11 employees
Biotechnology, Health and Wellness
Gladius Therapeutics vs
Leap Therapeutics
Leap Therapeutics United States

Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and develop...

Post Ipo Equity
51 employees
Biotechnology, Life Sciences
Gladius Therapeutics vs
PIC Therapeutics
PIC Therapeutics United States

Modulating Oncogene Translation to Dramatically Improve Cancer Patient Outcomes

Series A
8 employees
Biotechnology, Health Care

FAQ About Gladius Therapeutics

Developing groundbreaking therapies to disrupt mitochondrial function in cancer cells.
Gladius Therapeutics operates in the following industries: Biopharma, Biotechnology, Life Sciences.
Top alternatives and competitors to Gladius Therapeutics include Galera Therapeutics, Inc., Leap Therapeutics, PIC Therapeutics, Neurovir Therapeutics, G1 Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gladius Therapeutics and Galera Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Gladius Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy